Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Rifaximin

FDA-approved product (tablet, oral), marketed as Rifaximin, Xifaxan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Rifaximin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diarrhea
  • Hepatic failure
  • Infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antibiotics; Other antibiotics for topical use
FDA pharmacologic class
Rifamycin Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC A07AA11; WHO ATC D06AX11; FDA class Rifamycin Antibacterial

Repurposing investigation

Rifaximin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA93.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli70.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis87.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Rifaximin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Rifaximin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Rifaximin Versus Norfloxacin in Spontaneous Bacterial Peritonitis

    NCT04159870 · start 2019-11-05

    Registered record
    Registry ID
    NCT04159870
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Rifaximin; Norfloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-11-05
    Completion
    2021-12-20
    Enrolment
    322

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionRifaximin; Norfloxacin
    PhasePhase 3
    Registry statusUnknown

  • Autologous Transplant Targeted Against Crohn's

    NCT04154735 · start 2019-11

    Registered record
    Registry ID
    NCT04154735
    Conditions
    Crohn's Disease
    Interventions
    Fludarabine; Cyclophosphamide; Mesna; Alemtuzumab; G-CSF; Rifaximin; Tacrolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2019-11
    Completion
    2024-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn's Disease
    InterventionFludarabine; Cyclophosphamide; Mesna; Alemtuzumab +3 more
    PhasePhase 2
    Registry statusWithdrawn

  • Mesenchymal Stem Cells Treatment for Decompensated Liver Cirrhosis

    NCT03945487 · start 2019-05-20

    Registered record
    Registry ID
    NCT03945487
    Conditions
    Decompensated Liver Cirrhosis
    Interventions
    umbilical cord-derived mesenchymal stem cell; Comprehensive treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-05-20
    Completion
    2023-12-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDecompensated Liver Cirrhosis
    Interventionumbilical cord-derived mesenchymal stem cell; Comprehensive treatment
    PhasePhase 2
    Registry statusUnknown

  • Modulation of Gut Microbiota by Rifaximin in PD Patients

    NCT03958708 · start 2019-05-13

    Registered record
    Registry ID
    NCT03958708
    Conditions
    Parkinson Disease; Inflammation
    Interventions
    Rifaximin 550 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2019-05-13
    Completion
    2020-12-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Inflammation
    InterventionRifaximin 550 MG
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Trial of Rifaximin in Probable Alzheimer's Disease

    NCT03856359 · start 2019-04-09

    Registered record
    Registry ID
    NCT03856359
    Conditions
    Alzheimer's Disease
    Interventions
    Rifaximin 550 milligrams (MG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-09
    Completion
    2020-11-19
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer's Disease
    InterventionRifaximin 550 milligrams (MG)
    PhasePhase 2
    Registry statusCompleted

  • Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

    NCT03818672 · start 2019-01-29

    Registered record
    Registry ID
    NCT03818672
    Conditions
    Severe Hepatic Impairment
    Interventions
    Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-01-29
    Completion
    2020-02-02
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Hepatic Impairment
    InterventionRifaximin
    PhasePhase 4
    Registry statusTerminated

  • Efficacy of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis to Prevent ACLF Development

    NCT03780673 · start 2019-01-03

    Registered record
    Registry ID
    NCT03780673
    Conditions
    Liver Cirrhoses
    Interventions
    Simvastatin; Rifaximin; Placebo of Simvastatin; Placebo of Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2019-01-03
    Completion
    2022-12-01
    Enrolment
    254

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cirrhoses
    InterventionSimvastatin; Rifaximin; Placebo of Simvastatin; Placebo of Rifaximin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)

    NCT03515044 · start 2018-09-13

    Registered record
    Registry ID
    NCT03515044
    Conditions
    Overt Hepatic Encephalopathy
    Interventions
    40 mg Rifaximin SSD once daily; 40 mg Rifaximin SSD twice daily; 80 mg Rifaximin SSD once daily; 80 mg Rifaximin SSD twice daily; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-09-13
    Completion
    2020-03-12
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvert Hepatic Encephalopathy
    Intervention40 mg Rifaximin SSD once daily; 40 mg Rifaximin SSD twice daily; 80 mg Rifaximin SSD once daily; 80 mg Rifaximin SSD twice daily +1 more
    PhasePhase 2
    Registry statusCompleted

  • Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.

    NCT03469050 · start 2018-07-02

    Registered record
    Registry ID
    NCT03469050
    Conditions
    Diverticulitis
    Interventions
    Rifaximin delayed released 400mg Tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2018-07-02
    Completion
    2020-12-22
    Enrolment
    193

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiverticulitis
    InterventionRifaximin delayed released 400mg Tablet; Placebo
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Rifaximin on Visceral Hypersensitivity

    NCT03462966 · start 2018-07-01

    Registered record
    Registry ID
    NCT03462966
    Conditions
    Visceral Hypersensitivity; Irritable Bowel Syndrome
    Interventions
    Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2018-07-01
    Completion
    2021-11-19
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVisceral Hypersensitivity; Irritable Bowel Syndrome
    InterventionRifaximin
    PhasePhase 2
    Registry statusTerminated

  • Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

    NCT03069131 · start 2018-06-05

    Registered record
    Registry ID
    NCT03069131
    Conditions
    Cirrhosis; Ascites; Peritonitis
    Interventions
    Rifaximin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-06-05
    Completion
    2023-03-20
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis; Ascites; Peritonitis
    InterventionRifaximin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.

    NCT03115697 · start 2018-04-07

    Registered record
    Registry ID
    NCT03115697
    Conditions
    Refractory Hepatic Encephalopathy
    Interventions
    Lactulose; Rifaximin; Plasmapheresis
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Withdrawn
    Start
    2018-04-07
    Completion
    2019-04-15
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Hepatic Encephalopathy
    InterventionLactulose; Rifaximin; Plasmapheresis
    PhaseNot applicable
    Registry statusWithdrawn

  • Investigation of Fecal Microbiota Transplant in Chronic Intestinal Pseudo-obstruction Patients

    NCT06020365 · start 2018-01-01

    Registered record
    Registry ID
    NCT06020365
    Conditions
    Intestinal Pseudo-Obstruction; Fecal Microbiota Transplantation
    Interventions
    sequential fecal microbiota transplant combined with small intestinal fluid transplant
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-01-01
    Completion
    2023-08-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Pseudo-Obstruction; Fecal Microbiota Transplantation
    Interventionsequential fecal microbiota transplant combined with small intestinal fluid transplant
    PhaseNot applicable
    Registry statusCompleted

  • Plasma Free Amino Acids in Patients With Hepatic Encephalopathy

    NCT03306498 · start 2017-12-15

    Registered record
    Registry ID
    NCT03306498
    Conditions
    Hepatic Encephalopathy
    Interventions
    Aminoleban (8% amino acids infusion)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-12-15
    Completion
    2019-02-15
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatic Encephalopathy
    InterventionAminoleban (8% amino acids infusion)
    PhaseNot recorded
    Registry statusUnknown

  • Simvastatin Plus Rifaximin in Decompensated Cirrhosis

    NCT03150459 · start 2017-07-26

    Registered record
    Registry ID
    NCT03150459
    Conditions
    Cirrhoses, Liver
    Interventions
    Simvastatin 20 mg; Simvastatin 40mg; Rifaximin 400 mg; Placebo of Simvastatin; Placebo of Rifaximin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-07-26
    Completion
    2018-03-12
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhoses, Liver
    InterventionSimvastatin 20 mg; Simvastatin 40mg; Rifaximin 400 mg; Placebo of Simvastatin +1 more
    PhasePhase 2
    Registry statusCompleted